Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Proshares Trust (ZBIO) Total Current Liabilities (2023 - 2025)

Historic Total Current Liabilities for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to $52.4 million.

  • Zenas BioPharma's Total Current Liabilities rose 1914.68% to $52.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.4 million, marking a year-over-year increase of 1914.68%. This contributed to the annual value of $57.3 million for FY2024, which is 14633.24% up from last year.
  • As of Q3 2025, Zenas BioPharma's Total Current Liabilities stood at $52.4 million, which was up 1914.68% from $53.2 million recorded in Q2 2025.
  • Zenas BioPharma's 5-year Total Current Liabilities high stood at $57.3 million for Q4 2024, and its period low was $23.3 million during Q4 2023.
  • In the last 3 years, Zenas BioPharma's Total Current Liabilities had a median value of $50.8 million in 2025 and averaged $46.6 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first surged by 14633.24% in 2024, then skyrocketed by 1914.68% in 2025.
  • Zenas BioPharma's Total Current Liabilities (Quarter) stood at $23.3 million in 2023, then surged by 146.33% to $57.3 million in 2024, then dropped by 8.5% to $52.4 million in 2025.
  • Its Total Current Liabilities stands at $52.4 million for Q3 2025, versus $53.2 million for Q2 2025 and $49.1 million for Q1 2025.